Repligen
RGEN
#2161
Rank
$9.31 B
Marketcap
$165.05
Share price
-2.06%
Change (1 day)
39.06%
Change (1 year)
Categories

P/S ratio for Repligen (RGEN)

P/S ratio as of September 2026 (TTM): 12.2

According to Repligen 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.42. At the end of 2026 the company had a P/S ratio of 8.13.

P/S ratio history for Repligen from 2001 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20268.13-35.15%
202512.5-2.5%
202412.9-20.43%
202316.237.72%
202211.7-46.29%
202121.8-23.72%
202028.660.6%
201917.849.33%
201811.96.67%
201711.212.2%
20169.97-10.61%
201511.29.27%
201410.259.86%
20136.39103.04%
20123.15-8.06%
20113.42-37.77%
20105.50-10%
20096.1145.49%
20084.20-59.34%
200710.360.41%
20066.44-30.4%
20059.25-9.44%
200410.2-46.53%
200319.166.56%
200211.5-35.84%
200117.9

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Pfizer
PFE
2.50-79.51%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
4.96-59.39%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
6.67-45.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.71-77.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
0.8872-92.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
2.72-77.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
5.08-58.34%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
9.36-23.32%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
3.85-68.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
3.33-72.72%๐Ÿ‡บ๐Ÿ‡ธ USA